InCode BioPharmaceutics

InCode BioPharmaceutics is a biopharmaceutical company focused on the development of novel therapies for diseases caused by the dysregulation of the complement system. Originating as a spin-off from the Spanish National Research Council (CSIC), the company utilized its expertise in the alternative complement pathway to develop a pipeline of targeted inhibitors. Its research programs focus on high-unmet-need areas such as geographic atrophy and rare hematological disorders. In late 2019, InCode was acquired by Incyte Corporation, which integrated InCode's complement-targeting assets into its broader inflammation and autoimmunity pipeline.